靶向肠道菌群在非酒精性脂肪性肝炎中的机制及治疗进展

Mechanistic and therapeutic advances in non-alcoholic steatohepatitis by targeting the gut microbiota

目的综述肠道菌群影响非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)的作用机制,总结肠道菌群治疗非酒精性脂肪性肝炎的证据。方法通过查阅国内外文献,归纳了肠道菌群在NASH中的作用和基于肠道菌群治疗NASH的方法。结果肠道菌群能调节宿主能量代谢,增加机体内毒素和内源性乙醇,影响胆汁酸和胆碱代谢。通过益生菌/益生元/合生元、抗生素、中药治疗、调节饮食、运动及粪菌移植等方式能改变肠道菌群的组成,影响NASH的发展。结论肠道菌群的改变在NASH的进程中发挥重要作用,是NASH潜在的治疗靶点。

Objective To summarize the most recent advances in gut microbiota-mediated mechanisms,as well as gut microbiota-targeted therapies on non-alcoholic steatohepatitis(NASH).Methods The mechanisms of gut microbiota on NASH and the therapies of treating NASH based on gut microbiota were summarized by consulting literatures.Results Gut microbiota could regulate energy metabolism,increased endotoxin and endogenous ethanol,and affected bile acid and choline metabolism.Treatments as probiotics/probiotics/synbiotics,antibiotics,traditional Chinese medicine,diet regulation,exercise and fecal bacteria transplantation,changed the composition of gut microbiota,which affected the development of NASH.Conclusion Gut microbiota plays an important role in the process of NASH,and is a potential therapeutic target for NASH.